Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects

Published:2008-11-01 Issue:11 Volume:23 Page:3727-3729
ISSN:0931-0509
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:Nephrology Dialysis Transplantation

Author:

Abramowicz D.,Hadaya K.,Hazzan M.,Broeders N.,Hoang A.-D.,Ghisdal L.,Noel C.,Wissing K. M.

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ndt/article-pdf/23/11/3727/7629140/gfn332.pdf

Reference16 articles.

1. CONVERSION TO RAPAMYCIN IMMUNOSUPPRESSION IN RENAL TRANSPLANT RECIPIENTS: REPORT OF AN INITIAL EXPERIENCE1

2. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity

3. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent

4. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience

5. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rejection Challenges: Diagnosis and Management;Challenges in Pediatric Kidney Transplantation;2021

2. Opportunistic infections after conversion to belatacept in kidney transplantation;Nephrology Dialysis Transplantation;2020-02-01

3. Immunosuppression in Transplantation;National Kidney Foundation' s Primer on Kidney Diseases;2018

4. A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients;Clinical Transplantation;2016-03-14

5. Sirolimus-based, calcineurin inhibitor-free regimen in kidney transplant patients: An open-label, randomized, controlled trial;EUR J GEN MED;2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3